PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.1756
https://www.valueinhealthjournal.com/article/S1098-3015(18)35058-7/fulltext
Title :
PMS42 - SECUKINUMAB VERSUS ADALIMUMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS- A 52-WEEK COST PER RESPONDER ANALYSIS FROM THE PORTUGUESE PAYER PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)35058-7&doi=10.1016/j.jval.2018.09.1756
First page :
Section Title :
Open access? :
No
Section Order :
1121